A health worker in Portugal died two days after getting the COVID-19 vaccine. This comes as a shock to the world community and has raised questions over the safety and efficiency of the Pfizer vaccine.
A 32-year-old Mexican doctor experienced seizures, difficulty breathing and a skin rash after receiving the Pfizer-BioNTech COVID-19 vaccine.
California-based nurse tested positive after receiving the first dose of the Pfizer vaccine approved for emergency in the US.
A middle-aged Alaskan health worker has an allergic reaction after getting FDA-approved Pfizer COVID-19 vaccine.
The US vaccination programme aims to cover 100 million people by April. Meanwhile, a survey reveals that younger adults were more likely than older population to express willingness to get the COVID-19 vaccine.
Prime Minister Lee Hsien Loong said that the vaccines would be free, voluntary and given first to healthcare workers and the elderly, like him.
The warning came following reports of anaphylactoid reactions to the Pfizer-BioNTech Covid-19 in the UK. The two persons who have recovered now had a history of severe allergic reactions and carried adrenaline auto injectors.
"People with a history of significant allergic reactions should not be given the Pfizer/BioNTech Covid vaccine," UK health authorities said on Wednesday.
In its EUA application submitted to the DCGI, Pfizer India has sought permission to import its vaccine for sale and distribution in the country.
The United States is planning to distribute 6.4 million doses of the Pfizer'S Covid-19 vaccine in the first week after it is cleared for emergency use, which is likely next month.
Pfizer and BioNTech expect to seek U.S. authorization this month for emergency use of their vaccine.
After Corex, the government of India has banned the sale of another fixed dosage combination drug Vicks Action 500. Vicks Action 500 is manufactured by P&G, and its sale has been discontinued immediately.
Despite compulsory licensing, generic cancer drug too costly for the poor
Can grassroots innovations boost India's healthcare?
Ban on branded drugs could see India's $5.4 million free drugs-for-all policy work
A 32-year-old Mexican doctor experienced seizures, difficulty breathing and a skin rash after receiving the Pfizer-BioNTech COVID-19 vaccine.
California-based nurse tested positive after receiving the first dose of the Pfizer vaccine approved for emergency in the US.
A middle-aged Alaskan health worker has an allergic reaction after getting FDA-approved Pfizer COVID-19 vaccine.
The US vaccination programme aims to cover 100 million people by April. Meanwhile, a survey reveals that younger adults were more likely than older population to express willingness to get the COVID-19 vaccine.
Prime Minister Lee Hsien Loong said that the vaccines would be free, voluntary and given first to healthcare workers and the elderly, like him.
The warning came following reports of anaphylactoid reactions to the Pfizer-BioNTech Covid-19 in the UK. The two persons who have recovered now had a history of severe allergic reactions and carried adrenaline auto injectors.
"People with a history of significant allergic reactions should not be given the Pfizer/BioNTech Covid vaccine," UK health authorities said on Wednesday.
In its EUA application submitted to the DCGI, Pfizer India has sought permission to import its vaccine for sale and distribution in the country.
The United States is planning to distribute 6.4 million doses of the Pfizer'S Covid-19 vaccine in the first week after it is cleared for emergency use, which is likely next month.
Pfizer and BioNTech expect to seek U.S. authorization this month for emergency use of their vaccine.
After Corex, the government of India has banned the sale of another fixed dosage combination drug Vicks Action 500. Vicks Action 500 is manufactured by P&G, and its sale has been discontinued immediately.
Despite compulsory licensing, generic cancer drug too costly for the poor
Can grassroots innovations boost India's healthcare?
Ban on branded drugs could see India's $5.4 million free drugs-for-all policy work
